Integrating Ci-Ca therapy in your clinical practice.
Many critically ill patients in intensive care units (ICUs) are suffering from multi-organ failure and they depend on reliable application of organ support therapies.13
The multiFiltratePRO offers a wide range of therapeutic applications, mostly in intensive care, such as:
* Legal manufacturer of multiECCO2RÌýis EUROSETS S.r.l., Italy. Ä¢¹½´«Ã½ Deutschland GmbH is a distributor of multiECCO2RÌýin selected countries.
Explore the multiFiltratePRO
1ÌýWeidhase L et al. Plos One 2019; 14:e0215823
2ÌýEichhorn T et al. Blood Purif 2017; 44:260-266
3ÌýWeidhase et al. Crit Care 2020; 24:644
4ÌýHafner S et al. J Intensive Care 2015; 3:35
5ÌýBianchi NA et al. Blood Purif 2020; 49:567-575
6ÌýKalb R et al. Ther Apher Dial 2013; 17:202-212
7ÌýZarbock A et al. JAMA 2020;324:1629-1639
8ÌýMorgera et al. Crit Care Med 2009;37:2018-2024
9ÌýSlowinski T et al. Crit Care 2015; 19:349
10ÌýHoullé-Veyssière et al. Intensive Crit Care Nurs 2016; 36:35-41
11ÌýLink A et al. Crit Care 2012; 16:R97
12ÌýHuguet M et al. Int J Artif Organs 2017; 40:676-682
13ÌýICNARC. Case Mix Programme Summary Statistics 2019-20, www.icnarc.org/Our-Audit/Audits/Cmp/Reports/Summary-Statistics, accessed April 2021